JAK2 and Supraventricular tachycardia: In addition to JAK2, additional mutations in MPNs have a clear prognostic role, but their role in SVT pathogenesis is unclear, and there is no strong consensus among researchers regarding the use of non-JAK2-mutation screening in SVT patients.